Hasselt University / Universiteit Hasselt

A History and Perspective of Non-Fullerene Electron Acceptors for Organic Solar Cells (2021) Armin A, Li W, Sandberg OJ, Xiao Z, Ding L, Nelson J, Neher D, et al. Journal article, Review article Sn Substitution by Ge: Strategies to Overcome the Open-Circuit Voltage Deficit of Kesterite Solar Cells (2020) Choubrac L, Bär M, Kozina X, Felix R, Wilks RG, Brammertz G, Levcenko S, et al. Journal article Sodium Accumulates in the Skin of Psoriasis Patients and in Mice with Psoriasis-Like Skin Disease (2020) Marko L, Wild J, Rakova N, Balogh A, Opitz E, Linz P, Birukov A, et al. Conference contribution Heavy Alkali Treatment of Cu(In,Ga)Se-2 Solar Cells: Surface versus Bulk Effects (2020) Siebentritt S, Avancini E, Bär M, Bombsch J, Bourgeois E, Buecheler S, Carron R, et al. Journal article A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. (2020) Dangas GD, Tijssen JGP, Woehrle J, Sondergaard L, Gilard M, Moellmann H, Makkar RR, et al. Journal article Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study (2020) Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Journal article Moving exercise research in multiple sclerosis forward (the MoXFo initiative): Developing consensus statements for research (2020) Dalgas U, Hvid LG, Kwakkel G, Motl RW, de Groot V, Feys P, Op’t Eijnde B, et al. Journal article Exercise training for patients with type 2 diabetes and cardiovascular disease: What to pursue and how to do it. A Position Paper of the European Association of Preventive Cardiology (EAPC) (2019) Kemps H, Kraenkel N, Dorr M, Moholdt T, Wilhelm M, Paneni F, Serratosa L, et al. Journal article Sodium chloride triggers Th17 mediated autoimmunity (2019) Haase S, Wilck N, Kleinewietfeld M, Mueller DN, Linker R Journal article, Review article Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: final 5-year efficacy and safety results from the FUTURE 1 Phase 3 trial (2019) Tahir H, Mease PJ, Kavanaugh A, Reimold A, Rech J, Hall S, Geusens P, et al. Conference contribution